GKOS - FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients | Benzinga
The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
iDose TR is a long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods.
The FDA approval is based on results from two Phase 3 pivotal trials (GC-010 and ...